Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03715933 · ClinicalTrials.gov registry record · Phase 1
Phase 1 Study of INBRX-109 in Subjects With Locally Advanced or Metastatic Solid Tumors Including Sarcomas
A Phase 1 study of Ewing Sarcoma, sponsored by Inhibrx Biosciences.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 321
- Enrollment target
- 20
- Study locations
NCT03715933: Recruiting Phase 1 study of Ewing Sarcoma, sponsored by Inhibrx Biosciences.
NCT03715933 is a Phase 1 study of Ewing Sarcoma that is actively recruiting participants, run by Inhibrx Biosciences. The registered enrollment target is 321 participants, above the 97-participant average among 26 other Ewing Sarcoma trials with a reported enrollment target (231% higher). The trial reports 20 study locations across 12 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03715933, a Phase 1 study of Ewing Sarcoma, is actively recruiting participants, sponsored by Inhibrx Biosciences.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 321 participants
- Enrollment target
- 20
- Study locations
Study Summary
This is a first-in-human, open-label, non-randomized, three-part phase 1 trial of INBRX-109, which is a recombinant humanized tetravalent antibody targeting the human death receptor 5 (DR5).
Primary Outcome
Adverse events will be assessed and severity assigned by using the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE), version 5.0.
Conditions Studied
Interventions
- DRUG Temozolomide
- DRUG Irinotecan
- DRUG carboplatin
- DRUG pemetrexed
- DRUG INBRX-109
Study Locations (20)
California
- Precision NextGen Oncology and Research - Beverly Hills
- City of Hope - Duarte
- Valkyrie Clinical Trials - Los Angeles
- University of California, San Diego (UCSD) - Moores Cancer Center - San Diego
- University of California, San Francisco (UCSF) - San Francisco
- Sarcoma Oncology Center - Santa Monica
Michigan
- University of Michigan - Ann Arbor
- START Midwest Michigan, PC - Grand Rapids
Pennsylvania
- Children's Hospital of Philadelphia- Center for Childhood Cancer Research - Philadelphia
- University of Pennsylvania Abramson Cancer Center - Philadelphia
Texas
- UT MD Anderson Cancer Center - Houston
- NEXT Oncology - San Antonio
Arizona
- HonorHealth Research Institute - Scottsdale
Colorado
- University of Colorado Hospital - Aurora
Georgia
- Emory University - Winship Cancer Institute - Atlanta
Illinois
- The University of Chicago - Chicago
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 321 participants |
| Start Date | 2018-10-08 |
| Est. Completion | 2026-12 |
| Phase | Phase 1 |
What NCT03715933 shows while recruiting
NCT03715933 is an interventional study that assigns participants to a tested intervention. The registered 321 participants enrollment target is mid-sized for trials with a published cap, above the 97-participant average among 26 other Ewing Sarcoma trials with a reported enrollment target (231% higher).
The record links to 1 condition, with Ewing Sarcoma appearing as the primary indexed condition, and to 5 interventions - of which Temozolomide is the first listed.
NCT03715933 names 20 study sites across 12 states, led by California, Michigan, Pennsylvania.
Frequently Asked Questions
What is clinical trial NCT03715933 about?
NCT03715933 is a clinical study titled "Phase 1 Study of INBRX-109 in Subjects With Locally Advanced or Metastatic Solid Tumors Including Sarcomas". This is a first-in-human, open-label, non-randomized, three-part phase 1 trial of INBRX-109, which is a recombinant humanized tetravalent antibody targeting the human death receptor 5 (DR5).
What is the current status of trial NCT03715933?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 321 participants. The study started on 2018-10-08. Estimated completion is 2026-12.
What conditions does trial NCT03715933 study?
This clinical trial studies the following conditions: Ewing Sarcoma.
What interventions are being tested in trial NCT03715933?
The interventions under investigation include: Temozolomide (DRUG), Irinotecan (DRUG), carboplatin (DRUG), pemetrexed (DRUG), INBRX-109 (DRUG).
Who is sponsoring clinical trial NCT03715933?
This trial is sponsored by Inhibrx Biosciences, which has 6 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03715933 being conducted?
This trial has 20 study locations across Arizona, California, Colorado, Georgia, Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Ewing Sarcoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT03715933's enrollment target sits among peer trials
321 3rd of 26 higher than 24 of 26 other Ewing Sarcoma trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Ewing Sarcoma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Silmitasertib (CX-4945) in Combination With Chemotherapy for Relapsed Refractory Solid Tumors
RECRUITING · Phase 1
-
B7-H3-Specific Chimeric Antigen Receptor Autologous T-Cell Therapy for Pediatric Patients With Solid Tumors (3CAR)
RECRUITING · Phase 1
-
Alpha/Beta CD19+ Depleted Haploidentical Transplantation + Zometa for Pediatric Hematologic Malignancies and Solid Tumors
RECRUITING · Phase 1
-
Study of Autologous Tumor-Infiltrating Lymphocytes in Pediatric, Adolescent, and Young Adult Participants
RECRUITING · Phase 1
-
Selective Antigen Specific T Cells and CAR T Cells in Subjects With Relapsed/Refractory Embryonal Tumors (SABRE)
RECRUITING · Phase 1
-
Cabozantinib With Ifosfamide in Relapsed/Refractory Sarcomas
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05922878 · 321 participants · Phase 2
Study of ALTO-300 in MDD
- NCT04090359 · 322 participants · Phase 4
Dual Mobility Acetabular Cups in Revision TJA
- NCT04924075 · 322 participants · Phase 2
Belzutifan/MK-6482 for the Treatment of Advanced Pheochromocytoma/Paraganglioma (PPGL), Pancreatic Neuroendocrine Tumor (pNET), Von Hippel-Lindau (VHL) Disease-Associated Tumors, Advanced Gastrointestinal Stromal Tumor (wt GIST), or Solid Tumors With HIF-2α Related Genetic Alterations (MK-6482-015)
- NCT02763683 · 320 participants
Investigations of Dementia in Parkinson Disease
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI